Alex Wiltschko

And when they went back much later and they looked at that blood and they knew who had heart disease, who didn't have heart disease, they found a few things over time.

They found that this thing called cholesterol wasn't actually that great for your heart.

In fact, a subtype of cholesterol was the worst.

And they found that there is this molecule, you know, this class of molecules called statins that actually were really good for preventing heart disease.

And they found a whole host of other things.

It's called bioprospecting.

People still do it today.

So the kind of the big version of this that's happening in the UK is called the UK Biobank.

In the US, it's called All of Us.

And the idea is pretty simple.

I mean, the scientists like me like to gussied up with different words, but it's like, let's go fishing.

Let's collect everything that we can possibly collect.

And then maybe we can sort out something that's valuable after we do that for a long while.

Scent could become the new breath, but we need to do some bioprospecting.

We need a Framingham study equivalent for scent.

That hasn't been done.

And it's reasonable because the cost of analyzing a scent sample, or even in some ways how to even do it in the first place, the cost is high and how to do it's not that well established.

We've largely fixed the cost problem by building this company and kind of solving the problems we've had to solve.

And I think over time we'll solve the sampling problem.

And what's missing, frankly, is a nation state, that's the level, or an extremely wealthy individual or group of individuals to say, we want to do better than blood.